Cost Effectiveness of Peginterferon α-2a Plus Ribavirin versus Interferon α-2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepatitis C. The Authors’ Reply

被引：0
|
作者：
Sean D. Sullivan
Kavita Patel
Jesse Green
机构：
[1] University of Washington,
[2] Roche,undefined
来源：
PharmacoEconomics | 2004年 / 22卷
关键词：
Major Public Health Concern; Simulated Population; Incremental Benefit; Fibrosis Progression; Male Cohort;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：478 / 478
相关论文
共 50 条
  • [1] Cost effectiveness of peginterferon α-2a plus ribavirin versus interferon α-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C
    Sullivan, SD
    Craxi, A
    Alberti, A
    Giuliani, G
    De Carli, C
    Wintfeld, N
    Patel, KK
    Green, J
    PHARMACOECONOMICS, 2004, 22 (04) : 257 - 265
  • [2] Cost Effectiveness of Peginterferon α-2a Plus Ribavirin versus Interferon α-2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepatitis C
    Sean D. Sullivan
    Antonio Craxi
    Alfredo Alberti
    Giovanni Giuliani
    Claudio De Carli
    Neil Wintfeld
    Kavita K. Patel
    Jesse Green
    PharmacoEconomics, 2004, 22 : 257 - 265
  • [3] Cost Effectiveness of Peginterferon α-2a Plus Ribavirin versus Interferon α-2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepatitis C
    Miguel Arguedas
    PharmacoEconomics, 2004, 22 : 477 - 478
  • [4] Cost effectiveness of peginterferon α-2a plus ribavirin versus interferon α-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C
    Arguedas, M
    PHARMACOECONOMICS, 2004, 22 (07) : 477 - 478
  • [5] Cost effectiveness of peginterferon α-2a plus ribavirin versus interferon α-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.: The Author's Reply
    Sullivan, SD
    Patel, K
    Green, J
    PHARMACOECONOMICS, 2004, 22 (07) : 478 - 479
  • [6] Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C
    Siebert, U
    Sroczynski, G
    Rossol, S
    Wasem, J
    Ravens-Sieberer, U
    Kurth, BM
    Manns, MP
    McHutchison, JG
    Wong, JB
    GUT, 2003, 52 (03) : 425 - 432
  • [7] Efficacy and Tolerability of Pegylated Interferon-α2a plus Ribavirin versus Pegylated Interferon-α2b plus Ribavirin in Treatment-Naive Chronic Hepatitis C Patients
    Lee, Seok
    Kim, In Hee
    Kim, Seong Hun
    Kim, Sang Wook
    Lee, Seung Ok
    Lee, Soo Teik
    Kim, Dae Ghon
    Lee, Chang Seop
    Choi, Chang Soo
    Cho, Eun Young
    Kim, Haak Cheoul
    INTERVIROLOGY, 2010, 53 (03) : 146 - 153
  • [8] Randomized trial of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin for chronic hepatitis C in Japanese patients
    Shiho Miyase
    Katsuki Haraoka
    Yoshihiro Ouchida
    Yuko Morishita
    Shigetoshi Fujiyama
    Journal of Gastroenterology, 2012, 47 : 1014 - 1021
  • [9] Randomized trial of peginterferon α-2a plus ribavirin versus peginterferon α-2b plus ribavirin for chronic hepatitis C in Japanese patients
    Miyase, Shiho
    Haraoka, Katsuki
    Ouchida, Yoshihiro
    Morishita, Yuko
    Fujiyama, Shigetoshi
    JOURNAL OF GASTROENTEROLOGY, 2012, 47 (09) : 1014 - 1021
  • [10] Peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for treatment of chronic hepatitis C in treatment-naive Egyptian patients
    El-Wakil, R. M.
    Montasser, M. F.
    Mansour, M. A.
    Salman, T. A.
    EL-Batanony, M. H.
    Helail, E. H.
    Shehata, K. O.
    Attallah, K. M.
    Madwar, M. A.
    JOURNAL OF CLINICAL VIROLOGY, 2006, 36 : S142 - S143
12345